Stroke Biomarker Development Services

Biomarkers are measurable substances that can be used as objective indicators of disease diagnosis, treatment response and outcome prediction. In stroke, the number of candidate biomarkers is growing. These biomarkers include proteins, ribonucleic acid (RNA), lipids, or metabolites. Based on their relationship to stroke, these biomarkers may be associated with stroke burden and outcome through one or more mechanisms, including astrocyte activation, excitotoxicity, endothelial dysfunction, neuroplasticity or neurotrophicity, inflammation, fibrinolysis, metabolic abnormalities, and oxidative stress. Although biomarkers have the potential to improve the diagnosis and management of stroke patients, no marker has yet demonstrated sufficient sensitivity, specificity, speed, accuracy, and cost-effectiveness for routine stroke management, highlighting the need for further work.

Fig. 1. Process of discovery of stroke biomarkers and therapeutic targets. (Simats et al., 2016)

Our Services

At Ace Therapeutics, we are committed to developing stroke biomarkers to support mechanism of action, pharmacodynamic, prognostic and predictive preclinical studies throughout all phases of stroke drug development. Our team of experts is experienced in the screening, selection and validation of stroke biomarkers and can provide guidance at every step of the process.

Our stroke biomarker development services cover a wide range of capabilities, ensuring that our clients have access to the most comprehensive and innovative solutions.

By integrating technology platforms such as high-throughput genomics, transcriptomics, proteomics, and metabolomics, we help our clients discover new biomarkers and therapeutic targets for stroke and improve their understanding of stroke pathophysiology at multiple molecular levels.

Types of Stroke Biomarkers We Can Develop

Applications of Our Stroke Biomarker Development Services

Study the pathogenesis of stroke
Predict short- and long-term outcomes of stroke
Differentiate subtypes of stroke (e.g., ischemic vs. hemorrhagic)
Assess stroke severity and infarct volume
Contribute to the development of diagnostic methods for stroke
Evaluate efficacy and safety of stroke drugs
Pharmacokinetic/pharmacodynamic (PK/PD) modeling

Why Choose Us

Well-characterized in vivo and in vitro models of stroke that can be used for functional and efficacy evaluation.
Reliable bioinformatics solutions for systematic analysis of genomics, proteomics, metabolomics and transcriptomics data.
Expertise and technology platform (e.g., immunoassay, mass spectrometry) for the development of high-quality stroke biomarkers.
Customized biomarker development and validation services for your specific needs.

Ace Therapeutics can accelerate your stroke biomarker development program from early discovery to a fully validated assay. With a specialized development approach, we are the trusted partner for stroke biomarker development. Please do not hesitate to contact us if you have any questions.

Reference

Simats, A., et al. (2016). Neuroinflammatory biomarkers: from stroke diagnosis and prognosis to therapy. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1862(3), 411-424.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.